Interim Safety Analysis of the Prospective Phase 2 Trial "Retreatment with [ 177 Lu]Lu-PSMA-617" (Re-LuPSMA: NCT06288113) (EANM 2026) - Sep 29, 2026 - Abstract #EP-0935; P2 | "This interim analysis suggests that treatment-related SAEs are within an acceptable range in selected mCRPC patients undergoing retreatment with 177Lu-PSMA. This favorable safety profile may, in part, reflect the selection of patients who previously tolerated and responded well to initial 177Lu-PSMA therapy. Continued monitoring is warranted."
Clinical • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor
|
|
K. Kimura 1; J. Enke 1; L. Theus 1; A. Nguyen 1; J. Nikitas 2; A. Holzgreve 1, 3; J. Juarez 4; E. Kimura 1; Y. A. Gonzalez 1; C. Odum 1; M. Contreras 1; H. Alam 1; R. M. Nabong 1; S. Lira 1; S. Bahri 1; P. K. Gupta 1; A. Quon 1; A. Salavati 1; D. H. Silverman 1; M. Allen-Auerbach 1; J. Czernin 1; J. Calais 1
|